Overview

In biopharmaceutical manufacturing, viral clearance is a critical safeguard — protecting both products and patients. As regulatory expectations evolve, new modalities emerge, and sustainability pressures increase, strategies for ensuring viral safety must evolve too. Join global experts from CASTL, Avantor, and WuXi Biologics for an in-depth look at how the industry is adapting. This webinar will explore the fundamentals of viral clearance, present cutting-edge detergent technologies designed to replace Triton™ X-100 without compromising protein stability, and share over a decade of viral inactivation data — benchmarking future-ready viral safety solutions.

What You'll Learn

• Viral inactivation insights backed by 10+ years of data
• Emerging technologies reshaping viral clearance strategies
• Sustainable, GMP-ready alternatives to futureproof safety (incl. Triton™ X-100 replacements)

Speakers

• Hardik Upadhyay, CASTL – Bioprocessing specialist and training leader focused on process optimization, quality systems, and workforce development. 
• Victor Meléndez-Colón, PhD, Avantor – Industry veteran with decades of experience in CMC, technology transfer, and regulatory strategy. 
• Shanshan Wu, WuXi Biologics – Head of Viral Clearance Studies, overseeing 1,000+ IND and 150+ BLA studies worldwide.